Nomura Securities Remains Sidelined on Gap, Inc. (GPS); Q1 Review
Tweet
Share
E-mailGet Alerts GPS Hot Sheet
Price: $24.55 --0%
Rating Summary:
14 Buy, 23 Hold, 3 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 16 | New: 19
Rating Summary:
14 Buy, 23 Hold, 3 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 16 | New: 19
Join SI Premium – FREE
Nomura Securities maintains a 'Neutral' on Gap, Inc. (NYSE: GPS) price target of $25.00.
Analyst, Paul Lejuez, said, "GPS reported 1Q EPS of $0.47 vs. our est of $0.46, cons of $0.45 and guidance of $0.44-$0.46. Gap Brand is gaining momentum, helping to drive strong results in the qtr. If Gap Brand momentum continues, we believe there is upside potential to FY12 consensus forecasts (we are at $2.15 vs. cons of $1.97), though we do expect expense increases to limit some of the upside. We believe the risk/reward skews favorably, though the macro environment and the historical inconsistency of Gap Brand and Old Navy keep us on the sidelines."
For an analyst ratings summary and ratings history on Gap, Inc. click here. For more ratings news on Gap, Inc. click here.
Shares of Gap, Inc. closed at $26.31 yesterday.
Analyst, Paul Lejuez, said, "GPS reported 1Q EPS of $0.47 vs. our est of $0.46, cons of $0.45 and guidance of $0.44-$0.46. Gap Brand is gaining momentum, helping to drive strong results in the qtr. If Gap Brand momentum continues, we believe there is upside potential to FY12 consensus forecasts (we are at $2.15 vs. cons of $1.97), though we do expect expense increases to limit some of the upside. We believe the risk/reward skews favorably, though the macro environment and the historical inconsistency of Gap Brand and Old Navy keep us on the sidelines."
For an analyst ratings summary and ratings history on Gap, Inc. click here. For more ratings news on Gap, Inc. click here.
Shares of Gap, Inc. closed at $26.31 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Deutsche Bank Downgrades Workday (WDAY) to Hold
- Agios Pharma (AGIO) Reiterated at Overweight by Cantor Fitzgerald on Thalassemia Opportunity
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS ViewRelated Entities
NomuraSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
